These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 27609409)

  • 1. Treatment for severe eosinophilic asthma-consistent effect of anti-interleukin-5 antibodies?
    Castro M; Bacharier LB
    Lancet; 2016 Oct; 388(10056):2059-2060. PubMed ID: 27609409
    [No Abstract]   [Full Text] [Related]  

  • 2. Mepolizumab use: Post-approval academic practice experience.
    Benjamin MR; Bochner BS; Peters AT
    Ann Allergy Asthma Immunol; 2018 Jul; 121(1):126-128. PubMed ID: 29653234
    [No Abstract]   [Full Text] [Related]  

  • 3. Mepolizumab in the treatment of severe eosinophilic asthma: Results from a physician in the field.
    Strauss RA; Jawhari N
    Ann Allergy Asthma Immunol; 2018 Jul; 121(1):121-123. PubMed ID: 29684570
    [No Abstract]   [Full Text] [Related]  

  • 4. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
    Pelaia C; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Savino R; Pelaia G
    Drug Des Devel Ther; 2017; 11():3137-3144. PubMed ID: 29133975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reslizumab (Cinqair) for severe eosinophilic asthma.
    Med Lett Drugs Ther; 2016 Jun; 58(1497):81-2. PubMed ID: 27305070
    [No Abstract]   [Full Text] [Related]  

  • 6. [Severe refractory eosinophilic asthma].
    Jäger-Becker D
    MMW Fortschr Med; 2016 Feb; 158(3):67. PubMed ID: 27119709
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-Term Treatment With Anti-Interleukin 5 Antibodies in a Patient with Chronic Eosinophilic Pneumonia.
    Shimizu Y; Kurosawa M; Sutoh Y; Sutoh E
    J Investig Allergol Clin Immunol; 2020 Apr; 30(2):154-155. PubMed ID: 31778113
    [No Abstract]   [Full Text] [Related]  

  • 8. Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: one center's early clinical experience.
    Weir E; Paton J
    J Asthma; 2020 May; 57(5):521-524. PubMed ID: 30795693
    [No Abstract]   [Full Text] [Related]  

  • 9. Biomarkers for severe eosinophilic asthma.
    Yancey SW; Keene ON; Albers FC; Ortega H; Bates S; Bleecker ER; Pavord I
    J Allergy Clin Immunol; 2017 Dec; 140(6):1509-1518. PubMed ID: 29221581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
    Hilvering B; Xue L; Pavord ID
    Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting.
    Cameli P; Bergantini L; d'Alessandro M; Perruzza M; Cekorja B; Perillo F; Massa E; Ruzza A; Fossi A; Beltrami V; Sestini P; Bargagli E
    Int Arch Allergy Immunol; 2020; 181(8):606-612. PubMed ID: 32516771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benralizumab Normalizes Sputum Eosinophilia in Severe Asthma Uncontrolled by Anti-IL-5 Antibodies: A Single-Blind, Placebo-controlled Clinical Trial.
    Mukherjee M; Huang C; Venegas-Garrido C; Zhang K; Bhalla A; Ju X; O'Byrne PM; Svenningsen S; Sehmi R; Nair P
    Am J Respir Crit Care Med; 2023 Dec; 208(12):1330-1335. PubMed ID: 37824744
    [No Abstract]   [Full Text] [Related]  

  • 13. Biological treatment is approved for severe eosinophilic asthma.
    Mayor S
    BMJ; 2016 Nov; 355():i6472. PubMed ID: 27908911
    [No Abstract]   [Full Text] [Related]  

  • 14. Eosinophils and interleukin-5: the debate continues.
    Kay AB; Menzies-Gow A
    Am J Respir Crit Care Med; 2003 Jun; 167(12):1586-7. PubMed ID: 12796050
    [No Abstract]   [Full Text] [Related]  

  • 15. Reslizumab in the treatment of severe eosinophilic asthma: an update.
    Walsh GM
    Immunotherapy; 2018 Jun; 10(8):695-698. PubMed ID: 29554826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of chronic eosinophilic pneumonia successfully treated with mepolizumab.
    To M; Kono Y; Yamawaki S; Soeda S; Katsube O; Kishi H; To Y
    J Allergy Clin Immunol Pract; 2018; 6(5):1746-1748.e1. PubMed ID: 30201098
    [No Abstract]   [Full Text] [Related]  

  • 17. Secondary loss of response to mepolizumab in severe eosinophilic asthma.
    Cormier M; Chaboillez S; Lemiere C
    J Allergy Clin Immunol Pract; 2020 Feb; 8(2):736-738. PubMed ID: 31421278
    [No Abstract]   [Full Text] [Related]  

  • 18. Eosinophil-derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma.
    Howarth P; Quirce S; Papi A; Israel E; Mallett S; Bates S; Yancey S; Albers FC; Kwon N
    Allergy; 2020 Aug; 75(8):2085-2088. PubMed ID: 32147844
    [No Abstract]   [Full Text] [Related]  

  • 19. Severe Eosinophilic Allergic Asthma Responsive to Mepolizumab After Failure of 2 Consecutive Biologics.
    Sánchez-Jareño M; Barranco P; Romero D; Domínguez-Ortega J; Quirce S
    J Investig Allergol Clin Immunol; 2019 Feb; 29(1):79-81. PubMed ID: 30785114
    [No Abstract]   [Full Text] [Related]  

  • 20. Severe uncontrolled eosinophilic asthma, which responded to benralizumab after failure to respond to mepolizumab.
    Kurosawa M; Sutoh E
    Ann Allergy Asthma Immunol; 2019 Apr; 122(4):431-433. PubMed ID: 30578859
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.